Evidence map›Paper›PMID 38012513›Full record

ArticleBrazilian journal of microbiology : [publication of the Brazilian Society for Microbiology]2024

Synergism between molecules derived from Garcinia brasiliensis and antimicrobial drugs on field isolates of Mycoplasma hyopneumoniae.

Bruna Araújo Euzébio Alves Jacob Lopes, Leonardo Teófilo Toledo, Jessica Lobo Albuquerque Caldeira, Fábio Assad Feres Rodrigues, Mariana de Barros, Luiz Fernando Lino de Souza, Natália Fialho Gonzaga, Marcelo Henrique Dos Santos, Abelardo Silva-Júnior, Maria Aparecida Scatamburlo Moreira

Erratum issuedOpen access · greenAbstract read
In one paragraph

Article in Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology], 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Bruna Araújo Euzébio Alves Jacob Lopes *Department of Microbiology, Federal University of Viçosa, Viçosa, MG, Brazil.
Leonardo Teófilo Toledo *Department de Veterinary, Federal University of Viçosa, Viçosa, MG, Brazil.
Jessica Lobo Albuquerque CaldeiraDepartment de Veterinary, Federal University of Viçosa, Viçosa, MG, Brazil.
Fábio Assad Feres RodriguesDepartment of Biochemistry, Federal University of Viçosa, Viçosa, MG, Brazil.
Mariana de BarrosDepartment de Veterinary, Federal University of Viçosa, Viçosa, MG, Brazil.
Luiz Fernando Lino de SouzaDepartment de Veterinary, Federal University of Viçosa, Viçosa, MG, Brazil.
Natália Fialho GonzagaDepartment de Veterinary, Federal University of Viçosa, Viçosa, MG, Brazil.
Marcelo Henrique Dos SantosDepartment of Chemistry, Federal University of Viçosa, Viçosa, Brazil.
Abelardo Silva-JúniorInstitute of Biological and Health Sciences, Federal University of Alagoas, Maceió, AL, Brazil.
Maria Aparecida Scatamburlo MoreiraDepartment de Veterinary, Federal University of Viçosa, Viçosa, MG, Brazil. masm@ufv.br.ORCID http://orcid.org/0000-0002-6902-2502
Universidade Federal de Viçosa · BRUniversidade Federal de Alagoas · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Mycoplasma hyopneumoniae (M. hyopneumoniae) is one of the smallest free-living bacteria found in nature; it has an extremely small genome and lacks a cell wall. It is the main etiological agent of porcine enzootic pneumonia (EP), a chronic respiratory disease with worldwide distribution that causes significant losses in swine production. Due to the great economic impact caused by EP, new strategies for treating and controlling this agent are researched. The objective of this study was to verify the anti-M. hyopneumoniae activity of compounds derived from Garcinia brasiliensis and the synergism with the main antimicrobials used in the treatment of EP; this is the first study assessing the synergism between bioactive molecules and antimicrobial compounds in vitro against isolates of M. hyopneumoniae. The minimum inhibitory concentrations (MICs) of the antimicrobials tiamulin, valnemulin, and enrofloxacin, as well as the bioactive compounds guttiferone-A (Gut-A), 7-epiculsone (7-Epic), copper 7-epiculsone (7-Epic-Cu), and benzophenone, were determined. Subsequently, the interactions of antibiotics with the compounds were evaluated using the checkerboard method. Three field M. hyopneumoniae isolates were used, and the J strain was used as a control. The MIC values of the antimicrobials compared to the field isolates were equal to and lower than those of the reference strain J. Among the compounds used, 7-Epic-Cu showed the lowest MIC value. Synergistic association was observed for Gut-A with tiamulin and valnemulin, whereas 7-Epic and 7-Epic-Cu showed synergistic action with enrofloxacin. No synergistic effect was observed for benzophenone. Despite being an initial study, the results suggest that these combinations hold promise for the treatment of infections caused by M. hyopneumoniae.

Indexed as

Anti-Infective AgentsMycoplasma hyopneumoniaeAnimalsBenzophenonesCopperDiterpenesEnrofloxacinSwineAnti-Infective AgentsBenzophenonesCopperDiterpenesEnrofloxacintiamulinvalnemulinAntimicrobialsBioactive compoundsMinimum inhibitory concentrationSwine enzootic pneumonia

Identifiers

PMID38012513
PMCPMC10920607
OpenAlexW4389069011

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.